Avonex Share of First-Line Therapy Among Multiple Sclerosis Patients has Decreased Significantly Compared to One Year Ago, According to a Recent BioTrends Audit of 1000+ U.S. MS Patient Charts

Avonex Share of First-Line Therapy Among Multiple Sclerosis Patients has Decreased Significantly Compared to One Year Ago, According to a Recent BioTrends Audit of 1000+ U.S. MS Patient Charts

Virginia Schobel, 610-321-9431orChristopher Comfort, 781-993-2597

BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that while Biogen Idec’s Avonex and Teva’s Copaxone continue to capture almost one-half of multiple sclerosis (MS) patient share of first-line disease-modifying agent (DMA) therapy, Avonex share in 2012 (25 percent) has decreased significantly compared to the 2011 audit (29 percent). However, Avonex still represents a greater share of first-line therapy compared to Copaxone (21 percent). In , patients switching from first-line Avonex are significantly more likely to switch to second-line Novartis’s Gilenya (17 percent) compared to the previous year (9 percent). Copaxone, Biogen Idec / Elan’s Tysabri and Gilenya now split the overall majority of all second-line DMA therapy. While, in general, the choice of a specific DMA brand is frequently driven by the desire to impact disability progression and relapse rate, a comparison of self-reported perceptions and actual patient-level data suggests that CNS lesion reduction and product familiarity may play a greater role than neurologists realize in brand choice.

The recently publishedaudit also finds that 17 percent of DMA-treated patients have been tested with the STRATIFY JCV™ assay, which became commercially available in January 2012 for progressive multifocal leukoencephalopathy (PML) risk stratification for MS patients treated with Tysabri. Neurologists report that the majority of tested patients were checked with the assay because they were seen as possible candidates for Tysabri or were currently on Tysabri. In fact, 63 percent of audited patients currently treated with Tysabri have been tested with the anti-JC virus antibody assay. Prevalence of seropositive status (17 percent) among tested patients is similar to both self-reported estimates (29 percent) and 2011 patient-level seropositive prevalence (23 percent), but continues to be lower than expected based upon published clinical data (~55 percent). Regardless of serostatus, the majority of patients remain on their current DMA following testing.

When pushed to hypothetically choose one DMA in development to switch the audit patient to, 7 percent of audit patients were identified by the surveyed neurologists as potential candidates for Genzyme’s Aubagio, approved towards the end of audit fielding. Conversely, 26 percent of patients were identified as candidates for Biogen Idec’s BG-12. Compared to non-candidates, BG-12 candidates are significantly more likely to be on a second-line or later therapy, frequently Gilenya, and to have been tested with the STRATIFY JCV assay, suggesting that they had been considered a possible candidate for Tysabri.

is a syndicated annual patient audit designed to compare what physicians self-report about disease management to what actually occurs at the patient level. The 2012 audit captures information from 1034 patient charts provided by 224 U.S. neurologists in August and September 2012. All patients are on one of the commercially-available DMA brands (Avonex, Betaseron, Copaxone, Extavia, Gilenya, Rebif, Tysabri) at the time of the audit. Through an in-depth review of specific patient charts, details such as product initiation, switching, exacerbation management, and a host of laboratory tests and patient demographic variables help define patient types and identify therapy triggers. Patient profiles for the eight DMAs in late clinical development (Aubagio, BG-12, alemtuzumab, PEG-Avonex, Copaxone 40mg 3x weekly, daclizumab, laquinimod, ocrelizumab) are also characterized.

BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or . BioTrends is a Decision Resources Group company.

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at .

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.